These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20655888)

  • 1. Erroneous determination of hyperphosphatemia ('pseudohyperphosphatemia') in sera of patients that have been treated with liposomal amphotericin B (AmBisome).
    Jensen GM; Bunch TH; Wolf S; Laybourne S
    Clin Chim Acta; 2010 Dec; 411(23-24):1900-5. PubMed ID: 20655888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudohyperphosphatemia associated with high-dose liposomal and lipid complex amphotericin B when tested with Synchron LX 20 (Beckman/Coulter) phosphorous assay.
    Shiu JR; Forgie SE; Pinsk M; Romanick M
    J Pediatr Hematol Oncol; 2012 May; 34(4):e155-7. PubMed ID: 22146534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case-control study and case series of pseudohyperphosphatemia during exposure to liposomal amphotericin B.
    Bohm NM; Hoover KC; Wahlquist AE; Zhu Y; Velez JC
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6816-23. PubMed ID: 26282423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B as a cause of pseudohyperphosphatemia.
    Mendoza D; Connors S; Lane C; Stehnach S
    Clin Infect Dis; 2008 Feb; 46(4):645-6. PubMed ID: 18205543
    [No Abstract]   [Full Text] [Related]  

  • 5. Pseudohyperphosphatemia in children treated with liposomal amphotericin B.
    Miller MM; Johnson PN; Hagemann TM; Carter SM; Miller JL
    Am J Health Syst Pharm; 2014 Sep; 71(17):1462-8. PubMed ID: 25147170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
    Shah T; Lai WK; Gow P; Leeming J; Mutimer D
    Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal amphotericin B: clinical experience and perspectives.
    Gibbs WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B associated with severe hyperphosphatemia.
    Sutherland SM; Hong DK; Balagtas J; Gutierrez K; Dvorak CC; Sarwal M
    Pediatr Infect Dis J; 2008 Jan; 27(1):77-9. PubMed ID: 18162947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 90-year-old man with hyperphosphatemia.
    Lovekar S; Chen JL
    Am J Kidney Dis; 2011 Feb; 57(2):342-6. PubMed ID: 20951488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
    Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
    Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of liposomal amphotericin B (AmBisome) versus other lipid-based formulations.
    Heinemann V; Kähny B; Debus A; Wachholz K; Jehn U
    Bone Marrow Transplant; 1994; 14 Suppl 5():S8-9. PubMed ID: 7703929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperphosphatemia in an 11-year-old girl with acute myeloid leukemia: Answers.
    Albersen M; Bökenkamp A; Schotman H; Smetsers S
    Pediatr Nephrol; 2019 Apr; 34(4):627-629. PubMed ID: 30291428
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
    Petrikkos GL
    Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
    Ng TT; Denning DW
    Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
    Mattiuzzi GN; Estey E; Raad I; Giles F; Cortes J; Shen Y; Kontoyiannis D; Koller C; Munsell M; Beran M; Kantarjian H
    Cancer; 2003 Jan; 97(2):450-6. PubMed ID: 12518369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of liposomal amphotericin B in bone marrow transplant.
    Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
    J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
    Cordonnier C; Bresnik M; Ebrahimi R
    Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.